Melbourne, Australia, June 27, 2022 /PRNewswire/ — Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: DIH), (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceuticals and psychedelic medicine therapies for unmet medical needs, today announced that Dr. Paul LiknaitzkyHead of Clinical Psychedelic Research at Monash University and Principal Investigator of Incannex Psilocybin-Assisted Psychotherapy, will present an overview of the progress made in Incannex’s psychedelic medicine program at the HC Wainwright First Annual Mental Health Conference, which will take place June 27, 2022. Joel LathamManaging Director and CEO of Incanex, will host virtual meetings with institutional investors during the conference.
The on-demand presentation will be available for viewing beginning at 7 am US EDT in June 27, 2022. A webcast of the presentation will be available on the Incanex website at: https://www.incanex.com.au/investors/ and will be archived for a period of 90 days after the event.
This announcement has been approved for release to ASX by the Incanex Board of Directors.
About Incanex Healthcare Limited
Incannex is a clinical-stage pharmaceutical development company that is developing unique medical cannabis pharmaceuticals and psychedelic medicine therapies for the treatment of anxiety disorders, obstructive sleep apnea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, and inflammatory bowel disease. US FDA approval and registration, subject to continued clinical success, is being sought for each drug and therapy in development. Each indication represents major world markets and currently has limited or no registered pharmacotherapy treatments (drugs) available to the public.
Incannex has a strong patent filing strategy as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. Incannex is listed on the Australian Stock Exchange (ASX) under the stock ticker “IHL” and also has US Depository Shares listed on NASDAQ under the ticker “IXHL”.
Website: www.incanex.com.au
Investors: [email protected]
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date on which they were issued for the first time and are based on current expectations and estimates, as well as the beliefs and assumptions of management. Forward-looking statements included in this news release represent Inccanex’s views as of the date of this news release. Incannex anticipates that subsequent events and developments may cause their views to change. Incannex does not undertake any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon to represent Inccanex’s views as of any date after the date of this news release.
Contact information
Incannex Healthcare Limited
Mister Joel Latham
Managing Director and CEO
+61 409 840 786
[email protected]
US IR Contact
Rx communications group
miguel miller
+1-917-633-6086
[email protected]
See original content:https://www.prnewswire.com/news-releases/incanex-to-present-at-the-hc-wainwright-first-annual-mental-health-conference-301575448.html
SOURCE Incannex Healthcare Limited
